18 months! In 18 months there will be at least one and probably more DAA combinations ON THE MARKET is the US. If Biotron are not currently in the partnering process, and there is no sign of that, then they have missed the boat for HCV. Miller's presentation is more hope than substance, and flies in the face of the recent trials described at AASLD. Suggesting that ribavirin and N3a inhibitors will be used in these regimens is frankly bizarre, and does nothing for her credibility - but in fairness she is the CEO of a publicly-listed company so spin is pretty important.
questions for agm, page-53
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.001(5.26%) |
Mkt cap ! $18.04M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.9¢ | $6.191K | 315.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 963297 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1734532 | 5 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| BIT (ASX) Chart |